Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1098)
Drug Name
Mirtazapine
Synonyms
Mepirzapin; Mepirzepine; Mirtazapina; Mirtazapina [INN-Spanish]; Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirtazapinum; Mirtazapinum [INN-Latin]; Mirtazepine; Mirtazipine; Norset; ORG 3770; Org-3770; Promyrtil; Remergil; Avanza; Remergon; Remeron; Remeron SolTab; Zispin; mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 6-Azamianserin; 61337-67-5; 85650-52-8; CHEMBL654; EINECS 288-060-6; Rexer
Indication Depression [ICD11: 6A71] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 265.35 Topological Polar Surface Area 19.4
Heavy Atom Count 20 Rotatable Bond Count 0
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 3
Cross-matching ID
PubChem CID
4205
PubChem SID
9773 ; 4428328 ; 7847629 ; 7980003 ; 8152628 ; 10529734 ; 11114267 ; 11528962 ; 12013213 ; 14848184 ; 24724531 ; 26719854 ; 29215050 ; 29223310 ; 46386716 ; 46506965 ; 47434367 ; 47805076 ; 48416284 ; 49648465 ; 50028668 ; 56394976 ; 57309590 ; 57322193 ; 75519307 ; 85171706 ; 85174353 ; 85209954 ; 85787312 ; 92308611 ; 92714279 ; 103189247 ; 103857961 ; 104009532 ; 104305734 ; 117479056 ; 117843324 ; 124659131 ; 124800561 ; 125307817 ; 125324640 ; 125354423 ; 125433799 ; 126624260 ; 126655527 ; 126664368 ; 126683824 ; 129159156 ; 131377006 ; 131813308
ChEBI ID
ChEBI:6950
CAS Number
61337-67-5
TTD Drug ID
D05ZIK
Formula
C17H19N3
Canonical SMILES
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
InChI
1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChIKey
RONZAEMNMFQXRA-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
8-hydroxymirtazapine DM004457
11500131
Oxidation - 8-hydroxylation 1 [5]
Dimetilmirtazapine (DMR) DM004458 N. A. Unclear 1 [6]
Mirtazapine-N-oxide DM004455
46782381
Oxidation - N-oxidation 1 [7]
N-desmethylmirtazapine DM004456
10467350
Oxidation - N-demethylation 1 [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR004785 Mirtazapine Mirtazapine-N-oxide Oxidation - N-oxidation CYP3A [7]
MR004786 Mirtazapine N-desmethylmirtazapine Oxidation - N-demethylation CYP3A [5]
MR004787 Mirtazapine 8-hydroxymirtazapine Oxidation - 8-hydroxylation CYP1A2 ... [5]
MR004788 Mirtazapine Dimetilmirtazapine (DMR) Unclear CYP [6]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[3]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[3]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[4]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[4]
References
1 Mirtazapine was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
3 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
4 A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
5 Clinical pharmacokinetics of mirtazapine
6 Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study
7 FDA label:Mirtazapine

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.